← Back to Search

Behavioural Intervention

Repetitive Transcranial Magnetic Stimulation for Mild Cognitive Impairment

N/A
Recruiting
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 50-80 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after the intervention phase complete

Summary

This trial will use a personalized, non-invasive brain stimulation protocol to prevent cognitive decline in patients with mild cognitive impairment (MCI) and cognitively normal individuals at high risk of developing Alzheimer's disease (AD).

Who is the study for?
This trial is for English-speaking individuals aged 50-80 with mild cognitive impairment (MCI), who can attend daily sessions for 4 weeks, and haven't been in another study recently. They should have certain scores on cognitive tests like the MMSE or MoCA, be right-handed, and not have dementia.
What is being tested?
The study aims to prevent cognitive decline using repetitive transcranial magnetic stimulation (rTMS). It involves personalized brain stimulation guided by MRI imaging to enhance memory and delay Alzheimer's disease progression in those at high risk.
What are the potential side effects?
While rTMS is generally considered safe, potential side effects may include discomfort at the stimulation site, headache, lightheadedness, or rare seizures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 80 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after the intervention phase complete
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after the intervention phase complete for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Specimen sample
Other study objectives
Brain
Correction rate in memory association recall
NACC Neuropsychological batteries

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Inhibitory TBSExperimental Treatment1 Intervention
Inhibitory TBS
Group II: Excitatory TBSExperimental Treatment1 Intervention
Excitatory TBS
Group III: Sham TBSPlacebo Group1 Intervention
Sham TBS
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TBS
2022
N/A
~90

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
536 Previous Clinical Trials
159,880 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,789 Previous Clinical Trials
28,188,272 Total Patients Enrolled

Media Library

TBS (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT03962959 — N/A
Mild Cognitive Impairment Research Study Groups: Sham TBS, Excitatory TBS, Inhibitory TBS
Mild Cognitive Impairment Clinical Trial 2023: TBS Highlights & Side Effects. Trial Name: NCT03962959 — N/A
TBS (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03962959 — N/A
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top